Anti-tumor immunity induced by Interleukin-12 gene therapy in a metastatic model of breast cancer is mediated by natural killer cells
- 1 March 2000
- journal article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 60 (2) , 129-134
- https://doi.org/10.1023/a:1006318009608
Abstract
An intrahepatic tumor model for metastatic breast cancer was generated in syngeneic mice by direct inoculation of JC cells, a murine mammary adenocarcinoma cell line. Intratumoral administration of a recombinant adenoviral vector expressing the murine Interleukin-12 (ADV-mIL-12) resulted in significant reduction in the tumor volume compared to control vector. Tumor regression was also evident on histopathologic analysis of the liver, where inflammatory changes as opposed to nuclear atypia predominated after IL-12 vector treatment. There was a significant prolongation in the long term survival of IL-12 treated animals, with complete tumor rejection in 40% of the animals. In vivo depletion studies using specific monoclonal antibodies against the various lymphocyte subsets showed a significant reduction in long term survival after natural killer (NK) cell depletion. This suggests that the NK cell is a critical effector in the antitumor effect mediated by IL-12. These results strongly support the potential role of gene mediated cytokine therapy for the treatment of metastatic breastcancer.Keywords
This publication has 15 references indexed in Scilit:
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Direct Intratumoral Injection of an Adenovirus Expressing Interleukin-12 Induces Regression and Long-Lasting Immunity That Is Associated with Highly Localized Expression of Interleukin-12Human Gene Therapy, 1996
- A Role for the Interferon‐Inducible Protein 10 in Inhibition of Angiogenesis by Interleukin‐12Annals of the New York Academy of Sciences, 1996
- Adenovirus-Mediated Gene Transfer of Herpes Simplex Virus Thymidine Kinase in an Ascites Model of Human Breast CancerHuman Gene Therapy, 1996
- IL-12: a key cytokine in immune regulationImmunology Today, 1996
- Phenotypic and functional characteristics of in vivo-induced interleukin-12-activated killer cellsImmunology Letters, 1995
- CD4 T cells inhibitin vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genesEuropean Journal of Immunology, 1995
- DEMONSTRATION OF MHC CLASS I–SPECIFIC CYTOLYTIC ACTIVITY IN IL-2-ACTIVATED NK1+CD3+ CELLS AND EVIDENCE OF USAGE OF T AND NK CELL RECEPTORSTransplantation, 1994
- Management of metastatic breast cancerWorld Journal of Surgery, 1994
- Antitumor and antimetastatic activity of interleukin 12 against murine tumors.The Journal of Experimental Medicine, 1993